Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Methemoglobinemia In Rhesus Monkeys Due To M-Hemoglobinopathy

Osheiza Abdulmalik, DVM, MS, Larry Handt, DVM, MS, Martin Safo, PhD, Mary M Patterson, MS, DVM, Ping Wang, Caitlin A Fitzgerald, BS, Urs Giger, PD Dr. med. vet. MS FVH

Blood (2013) 122 (21): 4696.

https://doi.org/10.1182/blood.V122.21.4696.4696

Published: 2013

Journal Articles

Graft Versus Leukemia With Little Graft Versus Host Disease? Long Term Follow-Up Of a Study Using Transduced Donor T-Cells For Donor Leukocyte Transfusion

Eva M Weissinger, MD, Sylvia Borchers, PhD, Justyna Ogonek, MSc, Kriti Verma, MSc, Steve Ehrlich, MD, Christian Koenecke, MD, Patrick Schweier, Chiara Bonini, MD, Fabio Ciceri, Elke Dammann, Susanne Luther, Jürgen Krauter, Prof. Dr. med., Michael Stadler, MD, Arnold Ganser

Blood (2013) 122 (21): 4207.

https://doi.org/10.1182/blood.V122.21.4207.4207

Published: 2013

Journal Articles

Improved Modifications Of Nitric Oxide Donating Aspirin (NO-ASA): Getting a Grip On TP53 Mutated High-Risk Chronic Lymphocytic Leukemia (CLL)

Sylvia Krallman, Simon Jonas Poll-Wolbeck, Hanna Flamme, Mark Krueger, Albrecht Berkessel, PhD, Michael Hallek, MD, Karl-Anton Kreuzer, Dr. med.

Blood (2013) 122 (21): 4909.

https://doi.org/10.1182/blood.V122.21.4909.4909

Published: 2013

Journal Articles

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Anja Seckinger, MD, Tobias Meißner, PhD, Uta Bertsch, MD, Hans Salwender, MD, Jan Dürig, MD, Mathias Hänel, MD, Igor W. Blau, MD, Christof Scheid, MD, Katja Weisel, MD, Bernard Klein, PhD, Hartmut Goldschmidt, MD, Dirk Hose, Dr. med. dipl.-phys.

Blood (2013) 122 (21): 1863.

https://doi.org/10.1182/blood.V122.21.1863.1863

Published: 2013

Journal Articles

Role Of RECQ1 Helicase In Multiple Myeloma Biology and Drug Resistance

Elena Viziteu, Bernard Klein, PhD, Angelique Bruyer, Dirk Hose, Dr. med. dipl.-phys., Hartmut Goldschmidt, MD, Camille Grandmougin, Jihane Basbous, Angelos Constantinou, Jerome Moreaux, PhD

Blood (2013) 122 (21): 1889.

https://doi.org/10.1182/blood.V122.21.1889.1889

Published: 2013

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

Unbalanced Translocation t(5;17) Resulting In a TP53 Loss As Recurrent Aberration In Myelodysplastic Syndrome With Complex Karyotype

Gudrun Göhring, PD Dr. Med., Beate Vajen, Philipp A Greif, MD, Kathrin Thomay, Doris Steinemann, PhD, Sebastian Vosberg, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Stefan K. Bohlander, MD, Brigitte Schlegelberger, MD, PhD

Blood (2013) 122 (21): 4949.

https://doi.org/10.1182/blood.V122.21.4949.4949

Published: 2013

Journal Articles

Improved Outcome Of Stem Cell Transplantation for Severe Chronic Neutropenia With Or without Secondary Leukemia: A Long-Term Analysis of European Data For More Than 25 Years By the SCNIR

Cornelia Zeidler, MD/MPH, Anna Nickel, MPH, Karl-Walter Sykora, MD, Karl Welte, Prof. Dr. med.

Blood (2013) 122 (21): 3347.

https://doi.org/10.1182/blood.V122.21.3347.3347

Published: 2013

Journal Articles

Numerical Aberrations Involving The X Chromosome As a New Recurrent Aberration In Patients With Chronic Lymphocytic Leukemia

Beate Vajen, Dr. rer. nat., Kathrin Thomay, Dr. rer. nat., Winfried Hofmann, Dr. rer. nat., Brigitte Schlegelberger, MD, PhD, Gudrun Göhring, Dr. med.

Blood (2013) 122 (21): 4880.

https://doi.org/10.1182/blood.V122.21.4880.4880

Published: 2013

Journal Articles

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Blood (2013) 122 (21): 1847.

https://doi.org/10.1182/blood.V122.21.1847.1847

Published: 2013

Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Blood (2013) 122 (21): 3369.

https://doi.org/10.1182/blood.V122.21.3369.3369

Published: 2013

Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4071.

https://doi.org/10.1182/blood.V122.21.4071.4071

Published: 2013

Journal Articles

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Blood (2013) 122 (21): 404.

https://doi.org/10.1182/blood.V122.21.404.404

Published: 2013

Journal Articles

Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

Blood (2013) 122 (21): 439.

https://doi.org/10.1182/blood.V122.21.439.439

Published: 2013

Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Blood (2012) 120 (21): 412.

https://doi.org/10.1182/blood.V120.21.412.412

Published: 2012

Journal Articles

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Blood (2012) 120 (21): 229.

https://doi.org/10.1182/blood.V120.21.229.229

Published: 2012

Journal Articles

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Blood (2012) 120 (21): 2608.

https://doi.org/10.1182/blood.V120.21.2608.2608

Published: 2012

Journal Articles

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Anna T. Metodieva, Heike Pfeifer, MD, Afsar Mian, PhD, Anja Vogel, Hubert Serve, Prof. Dr. med., Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 2579.

https://doi.org/10.1182/blood.V120.21.2579.2579

Published: 2012

Journal Articles

The Activation of STAT3 and 5 in t(6;9)(DEK/CAN)-Positive Acute Myeloid Leukemia Models Is Inhibited by Exposure to Arsenic Trioxide

Claudia Oancea, Hannelore Held, Maria Heinssmann, Boris Brill, Hubert Serve, Prof. Dr. med., Martin Ruthardt, MD

Blood (2012) 120 (21): 1384.

https://doi.org/10.1182/blood.V120.21.1384.1384

Published: 2012

Journal Articles

T(6;9)-DEK/CAN-Positive Leukemia: Role of FLT3-ITD for the Determination of the Leukemic Phenotype

Maria Heinssmann, Lena Drangmeister, Katharina Schmid, Maren Keller, Hubert Serve, Prof. Dr. med., Claudia Oancea, Martin Ruthardt, MD, Gesine Bug

Blood (2012) 120 (21): 1316.

https://doi.org/10.1182/blood.V120.21.1316.1316

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Methemoglobinemia In Rhesus Monkeys Due To M-Hemoglobinopathy

Graft Versus Leukemia With Little Graft Versus Host Disease? Long Term Follow-Up Of a Study Using Transduced Donor T-Cells For Donor Leukocyte Transfusion

Improved Modifications Of Nitric Oxide Donating Aspirin (NO-ASA): Getting a Grip On TP53 Mutated High-Risk Chronic Lymphocytic Leukemia (CLL)

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Role Of RECQ1 Helicase In Multiple Myeloma Biology and Drug Resistance

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Unbalanced Translocation t(5;17) Resulting In a TP53 Loss As Recurrent Aberration In Myelodysplastic Syndrome With Complex Karyotype

Improved Outcome Of Stem Cell Transplantation for Severe Chronic Neutropenia With Or without Secondary Leukemia: A Long-Term Analysis of European Data For More Than 25 Years By the SCNIR

Numerical Aberrations Involving The X Chromosome As a New Recurrent Aberration In Patients With Chronic Lymphocytic Leukemia

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

The Activation of STAT3 and 5 in t(6;9)(DEK/CAN)-Positive Acute Myeloid Leukemia Models Is Inhibited by Exposure to Arsenic Trioxide

T(6;9)-DEK/CAN-Positive Leukemia: Role of FLT3-ITD for the Determination of the Leukemic Phenotype

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only